SCHEMBL27612401

SCHEMBL27612401

N#Cc1cc(-c2nc(N)nc(N)c2F)ccc1O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 2/20 0.42
▸ ESR2 Q92731 2/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ XDH P47989 1/20 0.41
▸ CHUK O15111 4/20 0.40
▸ USP7 Q93009 2/20 0.40
▸ IKBKB O14920 2/20 0.40
▸ ADORA2A P29274 6/20 0.40
▸ ADORA1 P30542 6/20 0.40
▸ ADORA2B P29275 2/20 0.40
▸ IL4 P05112 1/20 0.40
▸ F11 P03951 1/20 0.39
▸ HSD17B1 P14061 1/20 0.39
▸ HSD17B2 P37059 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21802136 0.81 PIK3CG (0.47) ESR1ESR2PIK3CGHSD17B1HSD17B2
SCHEMBL27631669 0.78 ADORA2A (0.55) ESR1ESR2PIK3CGADORA2AADORA1
SCHEMBL27613037 0.78 PIK3CG (0.44) ESR1ESR2PIK3CGADORA2AADORA1
SCHEMBL28753644 0.76 ADORA1 (0.49) CHUKADORA2AADORA1ADORA2B
SCHEMBL27631912 0.75 PIK3CG (0.44) PIK3CGADORA2AADORA1ADORA2B
SCHEMBL27631800 0.75 MCL1 (0.48) PIK3CGKDM4ETDP1
SCHEMBL27612525 0.74 ADORA2A (0.63) PIK3CGXDHCHUKADORA2AADORA1
SCHEMBL27612872 0.74 PIK3CG (0.56) PIK3CGCHUKUSP7IKBKBADORA2A
SCHEMBL27631926 0.73 PIK3CG (0.48) PIK3CGKDM4E
SCHEMBL1116418 0.72 PIK3CG (0.60) PIK3CGCHUKIKBKBADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1678321-A Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds RIGEL PHARMACEUTICALS INC (US) 2005-10-05 — — CN disclosed
Send feedback